nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.07.2013 | Original Paper

Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer

verfasst von: Ping-Hui Sun, Lin Ye, Malcolm D. Mason, Wen G. Jiang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Receptor-like protein tyrosine phosphatase kappa (PTPRK) has been shown to exhibit homophilic binding. It is a putative tumour suppressor in primary central nervous system lymphomas and colorectal cancer. The present study investigated the expression of PTPRK in breast cancer and the biological impact of PTPRK on breast cancer cells.

Methods

Expression of PTPRK protein and gene transcript was examined in a cohort of breast cancer patients. The association of PTPRK transcript level and pathological and clinical aspects was then analysed. Knockdown of PTPRK in breast cancer cells was performed using a specific anti-PTPRK transgene. The impact of PTPRK knockdown on breast cancer cells was investigated using in vitro cell function assays.

Results

Lower levels of PTPRK transcripts were seen in the advanced breast cancer. The reduced PTPRK transcript levels were associated with poor prognosis of the disease. PTPRK transcript levels were decreased in the primary tumours of patients who died from breast cancer or had metastases. Patients with lower expression of PTPRK had shorter survival compared with those higher expression levels of PTPRK. Knockdown of PTPRK resulted in increased proliferation, adhesion, invasion, and migration of breast cancer cells in vitro.

Conclusions

Decreased expression of PTPRK in breast cancer is correlated with poor prognosis. PTPRK is a negative regulator of adhesion, invasion, migration, and proliferation of breast cancer cells. This suggests that PTPRK is a potential tumour suppressor in breast cancer.

Angers-Loustau A, Cote JF, Tremblay ML (1999) Roles of protein tyrosine phosphatases in cell migration and adhesion. Biochem Cell Biol 77(6):493–505PubMedCrossRef

Ardini E, Agresti R, Tagliabue E, Greco M, Aiello P, Yang LT, Menard S, Sap J (2000) Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. Oncogene 19(43):4979–4987PubMedCrossRef

Bjorge JD, Pang A, Fujita DJ (2000) Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem 275(52):41439–41446PubMedCrossRef

Giefing M, Zemke N, Brauze D, Kostrzewska-Poczekaj M, Luczak M, Szaumkessel M, Pelinska K, Kiwerska K, Tonnies H, Grenman R, Figlerowicz M, Siebert R, Szyfter K, Jarmuz M (2011) High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. Genes Chromosomes Cancer 50(3):154–166PubMedCrossRef

Gyorffy B, Dietel M, Fekete T, Lage H (2008) A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma Int J Gynecol Cancer 18(6):1215–1233

Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MC (1995) Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res 55(21):5043–5048PubMed

Jiang WG, Hiscox SE, Parr C, Martin TA, Matsumoto K, Nakamura T, Mansel RE (1999) Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 5(11):3695–3703PubMed

Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE (2004) Differential expression of the CCN family members Cyr61 CTGF and Nov in human breast cancer. Endocr Relat Cancer 11(4):781–791PubMedCrossRef

Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mokbel K, Mansel RE (2005) Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 11(16):6012–6019PubMedCrossRef

Keane MM, Lowrey GA, Ettenberg SA, Dayton MA, Lipkowitz S (1996) The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res 56(18):4236–4243PubMed

Konishi N, Tsujikawa K, Yamamoto H, Ishida E, Nakamura M, Shimada K, Yane K, Yamashita H, Noguchi S (2003) Overexpression of leucocyte common antigen (LAR) P-subunit in thyroid carcinomas. Br J Cancer 88(8):1223–1228PubMedCrossRef

Kulas DT, Goldstein BJ, Mooney RA (1996) The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases. J Biol Chem 271(2):748–754PubMedCrossRef

LaForgia S, Morse B, Levy J, Barnea G, Cannizzaro LA, Li F, Nowell PC, Boghosian-Sell L, Glick J, Weston A et al (1991) Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21. Proc Natl Acad Sci USA 88(11):5036–5040PubMedCrossRef

Liu S, Sugimoto Y, Kulp SK, Jiang J, Chang HL, Park KY, Kashida Y, Lin YC (2002) Estrogenic down-regulation of protein tyrosine phosphatase gamma (PTP gamma) in human breast is associated with estrogen receptor alpha. Anticancer Res 22(6C):3917–3923PubMed

Motiwala T, Ghoshal K, Das A, Majumder S, Weichenhan D, Wu YZ, Holman K, James SJ, Jacob ST, Plass C (2003) Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene 22(41):6319–6331PubMedCrossRef

Motiwala T, Kutay H, Ghoshal K, Bai S, Seimiya H, Tsuruo T, Suster S, Morrison C, Jacob ST (2004) Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci USA 101(38):13844–13849PubMedCrossRef

Nakamura M, Kishi M, Sakaki T, Hashimoto H, Nakase H, Shimada K, Ishida E, Konishi N (2003) Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 63(4):737–741PubMed

Novellino L, De Filippo A, Deho P, Perrone F, Pilotti S, Parmiani G, Castelli C (2008) PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells. Cell Signal 20(5):872–883PubMedCrossRef

Ponniah S, Wang DZ, Lim KL, Pallen CJ (1999) Targeted disruption of the tyrosine phosphatase PTPalpha leads to constitutive downregulation of the kinases Src and Fyn. Curr Biol 9(10):535–538PubMedCrossRef

Sap J, Jiang YP, Friedlander D, Grumet M, Schlessinger J (1994) Receptor tyrosine phosphatase R-PTP-kappa mediates homophilic binding. Mol Cell Biol 14(1):1–9PubMed

Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O’Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA (2009) A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323(5922):1747–1750PubMedCrossRef

Stoker AW (2005) Protein tyrosine phosphatases and signalling. J Endocrinol 185(1):19–33PubMedCrossRef

Su J, Muranjan M, Sap J (1999) Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. Curr Biol 9(10):505–511PubMedCrossRef

Tabiti K, Smith DR, Goh HS, Pallen CJ (1995) Increased mRNA expression of the receptor-like protein tyrosine phosphatase alpha in late stage colon carcinomas. Cancer Lett 93(2):239–248PubMedCrossRef

Tonks NK (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7(11):833–846PubMedCrossRef

Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304(5674):1164–1166PubMedCrossRef

Wang SE, Wu FY, Shin I, Qu S, Arteaga CL (2005) Transforming growth factor beta (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. Mol Cell Biol 25(11):4703–4715PubMedCrossRef

Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD, Berchuck A, Bast RC Jr (1994) Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst 86(5):372–378PubMedCrossRef

Xu Y, Tan LJ, Grachtchouk V, Voorhees JJ, Fisher GJ (2005) Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. J Biol Chem 280(52):42694–42700PubMedCrossRef

Yang Y, Gil M, Byun SM, Choi I, Pyun KH, Ha H (1996) Transforming growth factor-beta1 inhibits human keratinocyte proliferation by upregulation of a receptor-type tyrosine phosphatase R-PTP-kappa gene expression. Biochem Biophys Res Commun 228(3):807–812PubMedCrossRef

Yang T, Zhang JS, Massa SM, Han X, Longo FM (1999) Leukocyte common antigen-related tyrosine phosphatase receptor: increased expression and neuronal-type splicing in breast cancer cells and tissue. Mol Carcinog 25(2):139–149PubMedCrossRef

Zhai YF, Beittenmiller H, Wang B, Gould MN, Oakley C, Esselman WJ, Welsch CW (1993) Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res 53(10 Suppl):2272–2278PubMed

Zheng XM, Wang Y, Pallen CJ (1992) Cell transformation and activation of pp 60c-src by overexpression of a protein tyrosine phosphatase. Nature 359(6393):336–339PubMedCrossRef

Zheng J, Kulp SK, Zhang Y, Sugimoto Y, Dayton MA, Govindan MV, Brueggemeier RW, Lin YC (2000) 17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells. Anticancer Res 20(1A):11–19PubMed

Zondag GC, Koningstein GM, Jiang YP, Sap J, Moolenaar WH, Gebbink MF (1995) Homophilic interactions mediated by receptor tyrosine phosphatases mu and kappa. A critical role for the novel extracellular MAM domain. J Biol Chem 270(24):14247–14250PubMedCrossRef

Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31(13):3406–3415PubMedCrossRef

Titel: Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer
verfasst von: Ping-Hui Sun
Lin Ye
Malcolm D. Mason
Wen G. Jiang
Publikationsdatum: 01.07.2013
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1421-5

Springer Medizin

Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2013

miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2

Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma

p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer

Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections

Optical techniques for the noninvasive diagnosis of skin cancer

Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie